Equine gastric disease treatment shifts toward subtype-specific care
A new sponsored educational article from The Horse brings equine gastric disease back into focus with a message many clinicians will recognize: diagnosis first, then treatment plus management. Published March 9, 2026, the piece features Dr. Ben Sykes and emphasizes that long-term success depends not just on medication, but on identifying the specific disease process, reducing risk factors, and repeating gastroscopy when needed to confirm resolution. (thehorse.com)
That framing reflects how the field has evolved. Equine gastric ulcer syndrome is no longer treated as a single, uniform condition. Reviews and clinical guidance increasingly separate equine squamous gastric disease, which is largely acid injury to the unprotected squamous mucosa, from equine glandular gastric disease, where impaired mucosal defense, inflammation, and management-related stressors appear to play a larger role. The distinction matters because treatment response differs, and recurrence remains a persistent challenge once pharmacologic therapy is stopped. (vetmed.illinois.edu)
On the pharmacology side, omeprazole remains the anchor drug in practice. The FDA-approved equine product label for GastroGard specifies 4 mg/kg for treatment, and notes that a 30-day follow-on course at 2 mg/kg prevented recurrence in 84% of treated horses in label studies. Industry and extension sources continue to describe omeprazole as the standard first-line therapy, especially for squamous disease. (drugs.com)
But newer research and conference reporting suggest the limits of oral omeprazole monotherapy are becoming harder to ignore for glandular disease. In EquiManagement’s coverage of 2024 AAEP Convention research, speakers reported stronger healing results for equine glandular gastric disease with esomeprazole and with long-acting injectable omeprazole than with daily oral omeprazole. The same report said oral omeprazole monotherapy is not recommended for EGGD, while misoprostol and sucralfate remain part of the discussion for selected cases, despite uneven evidence. Those findings should be interpreted cautiously because some data were presented in conference format rather than full peer-reviewed publication, but they point to where clinical practice may be heading. (equimanagement.com)
The new peer-reviewed nutraceutical study adds another useful piece. In the 2025 Equine Veterinary Journal trial, 30 horses with recent diagnoses of both ESGD and EGGD were randomized to placebo or a nutraceutical containing lecithin, pectin, and meadowsweet after omeprazole treatment. Only five horses remained ulcer-free by the end of the 4- to 8-week study, and the nutraceutical did not outperform placebo on gastroscopic recurrence outcomes. The authors did find shifts in salivary biomarkers that might suggest improved mucosal health, but they also noted those biomarkers need further validation. (pubmed.ncbi.nlm.nih.gov)
Expert and industry commentary remains broadly consistent on the management side. The Horse stresses that drug therapy should be paired with changes in feeding practices, stress reduction, and overall horse care. AAEP client-facing guidance similarly points to free-choice forage or more frequent feeding, less grain, and minimizing stressors such as confinement, hauling, and social disruption as core parts of prevention and treatment. In other words, even the best acid-suppression plan may fall short if the horse returns to the same ulcer-promoting environment. (thehorse.com)
Why it matters: For equine veterinarians, the bigger story is less about a single new drug than about a more disciplined treatment framework. Gastric disease workups increasingly need to define lesion location and type, set expectations about recurrence, and match therapy to subtype rather than using a one-size-fits-all ulcer protocol. That has implications for client communication, recheck scheduling, formulary choices, and conversations with pet parents about why management changes are not optional add-ons, but part of the treatment itself. It also reinforces the need to be careful with unapproved or compounded acid-suppression products, given longstanding regulatory concerns and variability in labeled content among some unapproved omeprazole products. (thehorse.com)
What to watch: The next phase of this story will likely center on better evidence for EGGD protocols, including injectable omeprazole schedules, esomeprazole, misoprostol, and combination regimens, as well as whether any adjunctive nutraceutical or biomarker approach can meaningfully reduce the high relapse rates seen after treatment ends. (pubmed.ncbi.nlm.nih.gov)